Literature DB >> 6750065

Effect of iron saturation on the bacteriostasis of human serum: in vivo does not correlate with in vitro saturation.

R S Baltimore, D G Shedd, H A Pearson.   

Abstract

Human serum inhibits the growth of a variety of human pathogens. One of the serum bacteriostatic components is transferrin, the major iron-binding protein. In the presence of transferrin, free iron, which is required for bacterial nucleoprotein synthesis, is unavailable and bacterial growth is inhibited. In an in vitro system, we tested the hypothesis that serum with highly saturated transferrin allows free iron to be available for rapid bacterial growth. We first confirmed the finding that addition of ionic iron sufficient to saturate transferrin in normal sera inhibits the bacteriostatic activity for Escherichia coli. In contrast, no differences were found in the growth rate of E. coli in sera from individuals representing the entire range of transferrin saturation found in humans (iron-deficient, normal, and thalassemic). This finding supports the thesis that iron added in vitro is more easily extracted than in vivo, where it is tightly bound to transferrin, and does not support the contention that ordinary iron treatment predisposes infants to infection.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6750065     DOI: 10.1016/s0022-3476(82)80693-8

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  3 in total

1.  Iron status in hypogammaglobulinaemia.

Authors:  H I Atrah
Journal:  J R Soc Med       Date:  1985-10       Impact factor: 5.344

2.  Iron deficiency in cystic fibrosis.

Authors:  P Ehrhardt; M G Miller; J M Littlewood
Journal:  Arch Dis Child       Date:  1987-02       Impact factor: 3.791

3.  Relative availability of transferrin-bound iron and cell-derived iron to aerobactin-producing and enterochelin-producing strains of Escherichia coli and to other microorganisms.

Authors:  J H Brock; P H Williams; J Licéaga; K G Wooldridge
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.